Drug Profile
Research programme: controlled-release therapeutics - Camurus
Alternative Names: CAM 2041; CAM 2046Latest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator Camurus
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pain; Postoperative pain
- Discontinued Diabetes mellitus; Inflammation
Most Recent Events
- 25 Aug 2023 Research programme is still in preclinical development in Pain in Sweden (Controlled release) (Camurus pipeline, August 2023)
- 25 Aug 2023 Research programme is still in preclinical development in Postoperative-pain in Sweden (Controlled release) (Camurus pipeline, August 2023)
- 25 Aug 2023 Discontinued - Preclinical for Diabetes mellitus in Sweden (unspecified route) (Camurus pipeline, August 2023)